Pembro Provides DFS Benefit in Early NSCLC

Adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to placebo in patients who had undergone complete resection, according to findings from the phase 3 PEARLS study.
Medscape Medical News

source https://www.medscape.com/viewarticle/971764?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?